Edition:
United Kingdom

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

8.30EUR
8:17am GMT
Change (% chg)

€-0.02 (-0.24%)
Prev Close
€8.32
Open
€8.35
Day's High
€8.37
Day's Low
€8.30
Volume
6,352
Avg. Vol
495,045
52-wk High
€16.88
52-wk Low
€7.28

Latest Key Developments (Source: Significant Developments)

Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - ALMIRALL SA ::ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​.TUDORZA REDUCES CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS AND DEMONSTRATES CARDIOVASCULAR SAFETY.‍​.  Full Article

Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​
Friday, 17 Nov 2017 

Nov 17 (Reuters) - ALMIRALL SA ::ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​.  Full Article

Almirall says Tildrakizumab launch in Europe moved to end-2018 or early 2019‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - ALMIRALL SA ::SAYS ANTICIPATED APPROVAL FOR TILDRAKIZUMAB AND ITS LAUNCH IN EUROPE ARE MOVED FROM MID-2018 TO END OF 2018 OR EARLY 2019.‍​.  Full Article

Almirall 9-month net result turns to loss of 99.7 mln euros YoY
Monday, 6 Nov 2017 

Nov 6 (Reuters) - ALMIRALL SA ::9-MONTH EBITDA 100.1 MILLION EUROS VERSUS 183.8 MILLION EUROS YEAR AGO.9-MONTH REVENUE 561.6 MILLION EUROS VERSUS 635.4 MILLION EUROS YEAR AGO.9-MONTH NET LOSS 99.7 MILLION EUROS VERSUS PROFIT 103.5 MILLION EUROS YEAR AGO.9-MONTH RESEARCH AND DEVELOPMENT EXPENSES 67.2 MILLION EUROS VERSUS 61.8 MILLION EUROS YEAR AGO.REITERATES ESTIMATES ANNOUNCED ON JULY 10.  Full Article

Almirall ends phase III research for nail psoriasis product in Europe
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - ALMIRALL SA ::TERMINATES ITS RESEARCH ACTIVITIES FOR P3073 PROGRAM (NAIL PSORIASIS) IN EUROPE IN PHASE III OF DEVELOPMENT.  Full Article

Almirall reduces FY 2017 revenue, net sales and EBITDA growth estimates
Monday, 10 Jul 2017 

July 10 (Reuters) - ALMIRALL SA ::PROVIDES UPDATE TO FY 2017 GUIDANCE THAT REDUCES INITIAL ESTIMATIONS FOR TOTAL REVENUES, NET SALES AND EBITDA GROWTH.SAYS FY 2017 GUIDANCE UPDATE TO TAKE ACCOUNT OF ADVERSE IMPACT OF RECENT MARKET DEVELOPMENTS IN US DERMATOLOGY.SEES FY 2017 EBITDA OF 140-170 MILLION EUROS.SEES LOW DOUBLE DIGIT DECLINE OF FY 2017 TOTAL REVENUE AND NET SALES VERSUS FY 2016.SAYS INVENTORY DESTOCKING, INAPPROPRIATE ADJUDICATION OF PATIENT ASSISTANCE PROGRAM AND GENERIC ACTICLATE WILL ADVERSELY IMPACT THE EARNINGS IN 2017.SAYS ITS BUSINESS IS PERFORMING IN LINE WITH EXPECTATIONS IN EUROPE AND REST OF THE WORLD.  Full Article

Almirall signs strategic deal with Nuevolution for skin diseases treatment
Monday, 12 Dec 2016 

Almirall SA : Signs strategic deal with Nuevolution for the treatment of inflammatory skin diseases and psoriatic arthritis . Nuevolution will receive an initial payment of 11.2 million euros ($11.9 million) and may receive additional payments for development and regulatory milestones of up to 172 million euros . Says agreement with Nuevolution could generate commercial milestones of up to 270 million euros .Nuevolution would also be entitled to receive royalties on the level of future net sales.  Full Article

Almirall announces positive phase III results for drug against psoriasis
Wednesday, 28 Sep 2016 

Almirall SA : Announces positive results from the phase III trial showing efficacy of dimethyl fumarate, a new systemic oral drug for patients with chronic plaque psoriasis .To present the results on Sep. 29 at the dermatology congress in Vienna.  Full Article

Almirall reports H1 net profit up at 80.5 million euros
Wednesday, 27 Jul 2016 

Almirall SA : H1 net profit 80.5 million euros ($88.53 million) versus 58.8 million euros year ago . Sees 2016 net result, EBITDA percent growth in the upper single digits range year-on-year . Sees 2016 total revenue percent growth in the upper single digits range year-on-year .H1 net sales 388.3 million euros versus 359.4 million euros year ago.  Full Article

Almirall H1 net profit 80.5 mln euros, up 37 pct year on year
Tuesday, 26 Jul 2016 

Almirall SA : H1 net profit 80.5 million euros versus 58.8 million euros year ago . H1 EBITDA 123.5 million euros versus 123.4 million euros year ago . H1 revenue 428.1 million euros versus 407.9 million euros year ago . H1 research and development expenses up 35 percent at 44.0 million euros versus 32.6 million euros year ago .Reiterates estimates for 2016.  Full Article

BRIEF-Almirall Announces Positive Top-Line Results From ASCENT Trial For Tudorza‍​

* ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE IV ASCENT TRIAL FOR TUDORZA‍​